Back


21/02/2020
Asarina Pharma AB (publ) Year-end 2019 Report released
Asarina Pharma AB today publishes its Q4 and Year-end report for 2019. CEO Peter Nordkild: “We have been very busy during an intensive last quarter of 2019 progressing Sepranolone in all three of our indications; PMDD, menstrual migraine and Tourette syndrome and raising SEK 48 million in a directed share issue.” [...]

Download the pdf file





X

X